

Strukturiertes Schriftenverzeichnis

Bibliometrische Basisdaten

Originalarbeiten	55
- davon als Erst- oder Letztautor	25
Übersichtsarbeiten, Editorials, Kommentare	15
- davon als Erst- oder Letztautor	12
Gesamtsumme der Impactfaktoren aller eigenen Publikationen	503,876
Gesamtsumme der Impactfaktoren aller Erst- oder Seniorautor Publikationen	308,368

- Publikationen mit Antragsbezug sind mit *** gekennzeichnet.
- Der Antragsteller hat bisher keine Förderung aus der internen Forschungsförderung erhalten.

Begutachtete Originalarbeiten als Erst- oder Letztautor

(* - geteilte Erstautorenschaft; # - geteilte Letztautorenschaft)

1. Gunesch AP, Zapatero-Belinchón FJ, Pinkert L, Steinmann E, Manns MP, Schneider G, Pietschmann T, Brönstrup M, **von Hahn T**. Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis. *Antimicrob Agents Chemother.* 2020 Jul 22;64(8):e00143-20. (*Impact Factor 2018: 4,715*)
2. Zapatero-Belinchón FJ, Dietzel E, Dolnik O, Döhner K, Costa R, Hertel B, Veselkova B, Kirui J, Klintworth A, Manns MP, Pöhlmann S, Pietschmann T, Krey T, Ciesek S, Gerold G, Sodeik B, Becker S, **von Hahn T**. *Viruses.* 2019 Mar 19;11(3):275. (*Impact Factor 2018: 3,816*)
3. *** Sandmann L, Dörge P, Wranke A, Vermehren J, Welzel TM, Berg CP, Grotenthaler JM, Weiss KH, Langel J, Sterneck M, von Wulffen M, Manns MP, Wedemeyer H, Hardtke S, **von Hahn T**. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. *Eur J Gastroenterol Hepatol.* 2019; 31(8):1049-1056. (*Impact Factor 2018: 2,198*)
4. *** Wang MC, Wandrer F, Schlué J, Voigtländer T, Lankisch TO, Manns MP, Bantel H, **von Hahn T**. Transjugular diagnostics in acute liver failure including measurements of hepato-central venous biomarker gradients. *Hepatol Res.* 2018; 48:914-925. (*Impact Factor 2018: 3,440*)
5. Thiele T, Manns MP, Lankisch TO, **von Hahn T**. Very low rates of *Helicobacter pylori* infection in organ transplant recipients presenting with peptic ulcer disease. *Acta Gastroenterol Belg.* 2017 Jan-Mar;80(1):25-30. (*Impact Factor 2018: 0,541*)
6. Westhaus S, Deest M, Nguyen ATX, Stanke F, Heckl D, Costa R, Schambach A, Manns MP, Berg T, Vondran FWR, Sarrazin C, Ciesek S, **von Hahn T**. Scavenger

- receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. *J Hepatol.* 2017 Aug;67(2):237-245. (*Impact Factor 2018: 16,510*)
7. Buchmann B, Döhner K, Schirdewahn T, Sodeik B, Manns MP, Wedemeyer H, Ciesek S, **von Hahn T**. A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. *Antiviral Res.* 2017; 141:116-123. (*Impact Factor 2018: 4,909*)
 8. Klintworth A, Nolden T, Westhaus S, Rohrmann K, David S, Manns MP, Finke S, Ciesek S, **von Hahn T**. Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells. *Antiviral Res.* 2015; 124:122-31. (*Impact Factor 2018: 4,909*)
 9. Solbach P, Westhaus S, Deest M, Herrmann E, Berg T, Manns MP, Ciesek S, Sarrazin C, **von Hahn T**. Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. *Cell Mol Gastroenterol Hepatol* 2015; 1:285–294. (*Impact Factor 2018: 7,076*)
 10. Van ND, Falk CS, Sandmann L, Vondran FW, Helfritz F, Wedemeyer H, Manns MP, Ciesek S, **von Hahn T**. Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. *Gut.* 2016; 65(6):1015-23. (*Impact Factor 2018: 19,819*)
 11. Veloso Alves Pereira I, Buchmann B, Sandmann L, Sprinzl K, Schlaphoff V, Döhner K, Vondran F, Sarrazin C, Manns MP, Pinto Marques Souza de Oliveira C, Sodeik B, Ciesek S, **von Hahn T**. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP). *PLoS One.* 2015;10(2):e0117152. (*Impact Factor 2018: 2,776*)
 12. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, Pöhlmann S, Vondran FW, David S, Manns MP, Ciesek S, **von Hahn T**. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. *J Antimicrob Chemother.* 2014; 69(8):2123-31. (*Impact Factor 2018: 5,217*)
 13. **von Hahn T**, Bange FC, Westhaus S, Rifai K, Attia D, Manns MP, Potthoff A, Gebel M. Ultrasound presentation of abdominal tuberculosis in a German tertiary care center. *Scand J Gastroenterol.* 2014; 49(2):184-90. (*Impact Factor 2018: 2,329*)
 14. Westhaus S, Bankwitz D, Ernst S, Rohrmann K, Wappler I, Agné C, Luchtefeld M, Schieffer B, Sarrazin C, Manns MP, Pietschmann T, Ciesek S, **von Hahn T**. Characterization of the inhibition of hepatitis C virus entry by In vitro-generated and patient-derived oxidized low-density lipoprotein. *Hepatology.* 2013; 57(5):1716-24. (*Impact Factor 2018: 14,679*)
 15. **von Hahn T**, Schiene-Fischer C, Van ND, Pfaender S, Karavul B, Steinmann E, Potthoff A, Strassburg C, Hamdi N, Abdelaziz AI, Sarrazin C, Müller T, Berg T, Trépo E, Wedemeyer H, Manns MP, Pietschmann T, Ciesek S. Hepatocytes that express variants of cyclophilin a are resistant to HCV infection and replication. *Gastroenterology.* 2012; 143:439-447. (*Impact Factor 2018: 20,877*)
 16. **von Hahn T**, Schulze A, Chicano Wust I, Heidrich B, Becker T, Steinmann E, Helfritz FA, Rohrmann K, Urban S, Manns MP, Pietschmann T, Ciesek S. The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus. *PLoS One.* 2011; 6: e24142. (*Impact Factor 2018: 2,776*)
 17. Ciesek S, Westhaus S, Wicht M, Wappler I, Henschen S, Sarrazin C, Hamdi N, Abdelaziz AI, Strassburg CP, Wedemeyer H, Manns MP, Pietschmann T, **von Hahn T**. Impact of occludin intra- and inter-species variation on its co-receptor function for authentic hepatitis C virus particles. *J Virol.* 2011; 85:7613-21. (*Impact Factor 2018: 4,370*)

18. **von Hahn T***, Ciesek S*, Wegener G, Plentz RR, Weismüller TJ, Wedemeyer H, Manns MP, Greten TF, Malek NP. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. *Scand J Gastroenterol.* 2011; 46:1092-8. (*Impact Factor 2018: 2,329*)
19. **von Hahn T***, Halangk J*, Witt H, Neumann K, Müller T, Puhl G, Neuhaus P, Nickel R, Beuers U, Wiedenmann B, Berg T. Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease. *Scand J Gastroenterol.* 2008; 43:584-92. (*Impact Factor 2018: 2,329*)
20. Evans MJ*, **von Hahn T***, Syder AJ, Panis M, Tscherne DM, Wölk B, Hatzioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. *Nature* 2007; 446:801-5. (*Impact Factor 2018: 42,778*)
21. **von Hahn T**, Yoon JC, Alter H, Rice CM, Rehmann B, Balfe P, McKeating JA. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. *Gastroenterology* 2007; 132:667-78. (*Impact Factor 2018: 20,877*)
22. Flint M*, **von Hahn T***, Zhang J, Farquhar M, Jones CT, Balfe P, Rice CM, McKeating JA. Diverse CD81 proteins support hepatitis C virus infection. *J Virol* 2006; 80:11331-42. (*Impact Factor 2018: 4,370*)
23. **von Hahn T**, Lindenbach B, Boullier A, Quehenberger O, Paulson M, Rice C, McKeating J. Oxidized low density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. *Hepatology.* 2006; 43:932-42. (*Impact Factor 2018: 14,679*)
24. **von Hahn T**, Stopik D, Koch M, Wiedenmann B, Dignass A. Management of severe refractory adult autoimmune enteropathy with infliximab and tacrolimus. *Digestion.* 2005;71:141-4. Case Report. (*Impact Factor 2018: 3,029*)
25. **von Hahn T**, Thiele I, Zingaro L, Hamm K, Garcia-Alzamora M, Kottgen M, Bleich M, Warth R. Characterization of the rat SK4/IK1 K⁺ channel. *Cell Physiol Biochem.* 2001; 11: 219-30. (*Impact Factor 2018: 5,500*)

Begutachtete Originalarbeiten als Koautor

1. Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer KH, Berger A, Matschenz K, Buggisch P, Backhus J, Ziser E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C; European HCV Resistance Study Group. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. *Clin Gastroenterol Hepatol.* 2021; 19(1):195-198. (*Impact Factor 2018: 8,549*)
2. Becker-Assmann J, Fard-Aghaie MH, Kantas A, Makridis G, Reese T, Wagner KC, Petersen J, Buggisch P, Stang A, **von Hahn T**, Oldhafer KJ. [Diagnostic and prognostic significance of α -fetoprotein in hepatocellular carcinoma]. *Chirurg.* 2020; 91(9):769-777. (*Impact Factor 2018: 0,669*)
3. *** Kirstein MM, Book T, Manns MP, **von Hahn T**, Voigtländer T. Secondary sclerosing cholangitis in critically ill patients has a poor outcome but lower tumour incidence than primary sclerosing cholangitis. *United European Gastroenterol J.* 2020; 8(6):716-724. (*Impact Factor 2018: 3,549*)
4. Schmidt CA, Keil C, Kirstein MM, Lehner F, Manns MP, **von Hahn T**, Lankisch TO, Voigtländer T. Dilatation Therapy and Demographic Characteristics Significantly Influence the Amount of Propofol for Therapeutic Endoscopic Retrograde Cholangiography. *Int J Hepatol.* 2019; 2019:4793096. (*Impact Factor 2018: 0,736*)

5. Dias J, Hengst J, Parrot T, Leeansyah E, Lunemann S, Malone DFG, Hardtke S, Strauss O, Zimmer CL, Berglin L, Schirdewahn T, Ciesek S, Marquardt N, **von Hahn T**, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Sandberg JK, Björkström NK. Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. *J Hepatol.* 2019; 71(2):301-312. (*Impact Factor 2018: 16,510*)
6. Voigtländer T, Schweitzer N, **von Hahn T**, Manns MP, Vogel A, Kirstein MM. Endoscopic biliary drainage in patients with cholangiocarcinoma - self-expanding metal versus polyethylene stents. *Scand J Gastroenterol.* 2019; 54:640-645. (*Impact Factor 2018: 2,329*)
7. Costa R, Todt D, Zapatero-Belinchón F, Schenk C, Anastasiou OE, Walker A, Hertel B, Timmer L, Bojkova D, Ruckert M, Sarrazin C, Timm J, Lohmann V, Manns MP, Steinmann E, **von Hahn T**, Ciesek S. SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. *J Hepatol.* 2019; 70:603-614. (*Impact Factor 2018: 16,510*)
8. Weiss AC, Bohnenpoll T, Kurz J, Blank P, Airik R, Lüdtke TH, Kleppa MJ, Deuper L, Kaiser M, Mamo TM, Costa R, **von Hahn T**, Trowe MO, Kispert A. Delayed onset of smooth muscle cell differentiation leads to hydroureter formation in mice with conditional loss of the zinc finger transcription factor gene *Gata2* in the ureteric mesenchyme. *J Pathol.* 2019. doi: 10.1002/path.5270. [Epub ahead of print] (*Impact Factor 2018: 6,253*)
9. Herrmann A, Sandmann L, Adams O, Herrmann D, Dirks M, Widera M, Westhaus S, Kaiser R, di Cristanziano V, Manns MP, Korth J, Richter N, Anastasiou O, Timm J, **von Hahn T**, Ciesek S. Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment. *J Med Microbiol.* 2018 Oct;67(10):1496-1508. (*Impact Factor 2018: 0,988*)
10. Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, Wedemeyer H, **von Hahn T**, Stremmel W, Pathil A, Seybold U, Schott E, Blessin U, Sarrazin C, Welker M, Harrer E, Scholten S, Hinterleitner C, Lauer UM, Malek NP, Berg CP. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. *PLoS One.* 2018 Jun 6;13(6):e0197544. (*Impact Factor 2018: 2,776*)
11. Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, **von Hahn T**, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. *Gastroenterology.* 2018; 154(4):976-988. (*Impact Factor 2018: 20,877*)
12. Ciesek S, Proske V, Otto B, Pischke S, Costa R, Lütthgehetmann M, Polywka S, Klempnauer J, Nashan B, Manns MP, **von Hahn T**, Lohse AW, Wedemeyer H, Mix H, Sterneck M. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. *Transpl Infect Dis.* 2016; 18(3):326-32. (*Impact Factor 2018: 2,071*)
13. Lauer J, Potthoff A, Mc Cavert M, Marquardt S, Vaske B, Rosenthal H, **von Hahn T**, Wacker F, Meyer BC, Rodt T. Comparison of Technical and Clinical Outcome of Transjugular Portosystemic Shunt Placement Between a Bare Metal Stent and a PTFE-Stentgraft Device. *Cardiovasc Intervent Radiol.* 2016; 39(4):547-56. (*Impact Factor 2018: 1,928*)
14. Stöhr S, Costa R, Sandmann L, Westhaus S, Pfaender S, Anggakusuma, Dazert E, Meuleman P, Vondran FW, Manns MP, Steinmann E, **von Hahn T**, Ciesek S. Host cell mTORC1 is required for HCV RNA replication. *Gut.* 2016; 65(12):2017-2028. (*Impact Factor 2018: 19,819*)

15. Heidrich B, Pischke S, Helfritz FA, Mederacke I, Kirschner J, Schneider J, Raupach R, Jäckel E, Barg-Hock H, Lehner F, Klempnauer J, **von Hahn T**, Cornberg M, Manns MP, Ciesek S, Wedemeyer H. Hepatitis C virus core antigen testing in liver and kidney transplant recipients. *J Viral Hepat.* 2014; 21(11):769-79. (*Impact Factor 2018: 3,561*)
16. Deest M, Steinmann E, Manns MP, **von Hahn T**, Ciesek S. Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization. *Antiviral Res.* 2014; 101:37-44. (*Impact Factor 2018: 4,909*)
17. Catanese MT, Loureiro J, Jones CT, Dorner M, **von Hahn T**, Rice CM. Different requirements for SR-BI in hepatitis C virus cell-free versus cell-to-cell transmission. *J Virol.* 2013; 87:8282-93. (*Impact Factor 2018: 4,370*)
18. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Krämer-Kühl A, Welsch K, Winkler M, Meyer B, Drosten C, Dittmer U, **von Hahn T**, Simmons G, Hofmann H, Pöhlmann S. The spike-protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2 and is targeted by neutralizing antibodies. *J Virol.* 2013; 87:5502-11. (*Impact Factor 2018: 4,370*)
19. Sandmann L, Wilson M, Back D, Wedemeyer H, Manns MP, Steinmann E, Pietschmann T, **von Hahn T**, Ciesek S. Anti-retroviral drugs do not facilitate Hepatitis C Virus (HCV) infection in vitro. *Antiviral Res.* 2012; 96:51-8. (*Impact Factor 2018: 4,909*)
20. Ciesek S, **von Hahn T**, Colpitts CC, Schang LM, Friesland M, Steinmann J, Manns MP, Ott M, Wedemeyer H, Meuleman P, Pietschmann T, Steinmann E. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. *Hepatology.* 2011; 54:1947-55. (*Impact Factor 2018: 14,679*)
21. Bekker V, Chanock SJ, Yeager M, Hutchinson AA, **von Hahn T**, Chen S, Xiao N, Dotrang M, Brown M, Busch MP, Edlin BR, Rice CM, O'Brien TR. Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection. *J Viral Hepat.* 2010; 17:192-200. (*Impact Factor 2018: 3,561*)
22. Keck Z, Li S, Xia J, **von Hahn T**, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM, Fong SK. Mutations in HCV E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. *J Virol.* 2009; 83:6149-60. (*Impact Factor 2018: 4,370*)
23. Ciesek S, Steinmann E, Wedemeyer H, Manns MP, Neyts J, Tautz N, Madan V, Bartenschlager R, **von Hahn T**, Pietschmann T. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. *Hepatology.* 2009; 50:1638-45. (*Impact Factor 2018: 14,679*)
24. Catanese MT, Graziani R, **von Hahn T**, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. *J Virol* 2007; 81:8063-71. (*Impact Factor 2018: 4,370*)
25. Tscherne DM, Evans MJ, **von Hahn T**, Jones CT, Stamataki Z, McKeating JA, Lindenbach BD, Rice CM. Superinfection exclusion in cells infected with hepatitis C virus. *J Virol* 2007; 81:3693-703. (*Impact Factor 2018: 4,370*)
26. Heitzmann D, Grahmmer F, **von Hahn T**, Schmitt-Graff A, Romeo E, Nitschke R, Gerlach U, Lang HJ, Verrey F, Barhanin J, Warth R. Heteromeric KCNE2/KCNQ1 potassium channels in the luminal membrane of gastric parietal cells. *J Physiol.* 2004; 561: 547-57. (*Impact Factor 2018: 4,547*)
27. Kerst G, Beschorner U, Unsold B, **von Hahn T**, Schreiber R, Greger R, Gerlach U, Lang HJ, Kunzelmann K, Bleich M. Properties and function of KCNQ1 K⁺ channels

isolated from the rectal gland of *Squalus acanthias*. *Pflugers Arch.* 2001; 443: 146-54. (*Impact Factor 2018: 2,765*)

28. Kunzelmann K, Hübner M, Schreiber R, Levy-Holzman R, Garty H, Bleich M, Warth R, Slavik M, **von Hahn T**, Greger R. Cloning and function of the rat colonic epithelial K⁺ channel KVLQT1. *J Membr Biol.* 2001; 179: 155-64. (*Impact Factor 2018: 1,991*)
29. Mauricio AC, Slawik M, Heitzmann D, **von Hahn T**, Warth R, Bleich M, Greger R. Deoxycholic acid (DOC) affects the transport properties of distal colon. *Pflugers Arch.* 2000; 439: 532-40. (*Impact Factor 2018: 2,765*)
30. Warth R, Hamm K, Bleich M, Kunzelmann K, **von Hahn T**, Schreiber R, Ullrich E, Mengel M, Trautmann N, Kindle P, Schwab A, Greger R. Molecular and functional characterization of the small Ca²⁺-regulated K⁺ channel (rSK4) of colonic crypts. *Pflugers Arch.* 1999; 438: 437-44. (*Impact Factor 2018: 2,765*)

Übersichtsartikel in Zeitschriften

1. **von Hahn T**, Ringe KI, Potthoff A. [Diseases and diagnosis of the biliary system : When does the gastroenterologist need the radiologist?] *Radiologe.* 2019; 59:293-299. (*Impact Factor 2018: 0,382*)
2. Ciesek S, **von Hahn T**. Expression Cloning of Host Factors Required for the HCV Replication Cycle. *Methods Mol Biol.* 2019; 1911:169-182. (*Impact Factor 2018: 10,710*)
3. Busch M, Schneider A, Lankisch T, **von Hahn T**. Acute hemorrhage in the upper gastrointestinal tract. *Internist (Berl).* 2017; 58(3):226-232. (*Impact Factor 2018: 0,440*)
4. Pfaender S, **von Hahn T**, Steinmann J, Ciesek S, Steinmann E. Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy. *Rev Med Virol.* 2016; 26(5):330-9. (*Impact Factor 2018: 4,221*)
5. **von Hahn T**, Ciesek S. Cyclophilin polymorphism and virus infection. *Curr Opin Virol.* 2015 Aug 13;14:47-49. (*Impact Factor 2018: 5,400*)
6. Manns MP, **von Hahn T**. Novel Therapies for Hepatitis C – One Pill Fits All? *Nature Reviews Drug Discov.* 2013.12:595-610. (*Impact Factor 2018: 64,797*)
7. **von Hahn T**. Virale Infektion von Hepatozyten. *Dtsch Med Wochenschr.* 2012. 137:2448-52. (*Impact Factor 2018: 0,569*)
8. Ciesek S, **von Hahn T**, Manns MP. Second-wave protease inhibitors: choosing an heir. *Clin Liver Dis.* 2011; 15:597-609. (*Impact Factor 2018: 0,372*)
9. **von Hahn T**, Ciesek S, Manns MP. Arrest all accessories - inhibition of hepatitis C virus by compounds that target host factors. *Discov Med.* 2011; 12:237-44. (*Impact Factor 2018: 1,903*)
10. Mederacke, I, **von Hahn T**. Molekulare Diagnostik und zukünftige Therapien bei Hepatitis C. *Gastroenterologe.* 2011; 6:98–105. (*Impact Factor 2018: 0,090*)
11. **von Hahn T**, Steinmann E, Ciesek S, Pietschmann T. Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. *Expert Rev Gastroenterol Hepatol.* 2010; 4:63-79. (*Impact Factor 2018: 2,991*)
12. **von Hahn T**, Rice CM. Hepatitis C virus entry. *J Biol Chem* 2008; 283:3689-93. (*Impact Factor 2018: 4,238*)
13. Tellinghuisen TL, Evans MJ, **von Hahn T**, You S, Rice CM. Studying hepatitis C virus: making the best of a bad virus. *J Virol* 2007; 81:8853-67. (*Impact Factor 2018: 4,370*)

Editorials

1. Mederacke I, von Hahn T. Survival of the fittest: selection of hepatitis C virus variants during liver graft reinfection. *Hepatology*. 2011; 53:705-8. (*Impact Factor 2018: 14,679*)
2. von Hahn T, McKeating JA. In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube. *J Hepatol* 2007; 46:355-8. (*Impact Factor 2018: 16,510*)

Buchkapitel

1. von Hahn T. Parasitosen und bakterielle Lebererkrankungen. In: *Praxis der Hepatologie*. Hrsg. Schneidewind S, Manns MP. Springer Berlin Heidelberg. 2016: 81-86.